Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Andrew Dudum, Director and CEO of Hims & Hers Health, Inc. (HIMS), reported multiple transactions on 08/18/2025 conducted under a Rule 10b5-1 plan. The filing shows option exercises at an exercise price of $2.43 for 17,001 and 108,334 options, and subsequent sales of shares from those exercises and existing holdings at average weighted prices in the mid-$44 to mid-$45 range. Reported sales on that date include blocks of 47,534; 2,792; 17,001; 41,667; 50,000; and 16,667 shares at various average prices around $44.76–$45.42. Post-transaction beneficial ownership across direct and indirect holdings is reported for numerous trusts, with notable indirect positions such as 1,016,871 and 2,214,769 shares held by trustees. The Form 4 is signed by an attorney-in-fact on 08/20/2025.
Form 144 notice for Hims & Hers Health, Inc. (HIMS) reports proposed and recent sales of Class A common stock by insiders and related parties. The filing lists a proposed sale of 47,534 shares via Fidelity (approximate market value $2,141,494) with an approximate sale date of 08/18/2025 on the NYSE. It shows acquisition details for 46,534 vested restricted shares received in 2022 and 2023 as compensation. The filing also discloses multiple completed insider sales between 06/16/2025 and 07/21/2025 totaling several hundred thousand shares and gross proceeds in the multi‑million dollar range. The filer certifies they are not aware of undisclosed material adverse information.
Form 144 notice for HIMS (Class A) shows a proposed sale of 128,127 Class A shares with an aggregate market value of $5,793,902.94, scheduled approximately for 08/18/2025. The filing reports that 125,335 of those shares derive from an option granted on 06/17/2020 and are to be sold for cash on 08/18/2025, while 2,792 shares were acquired by restricted stock vesting on 06/15/2024 as compensation. The issuer's outstanding Class A shares are reported as 217,641,958. The filing also discloses multiple Class A sales by Andrew Dudum and the Dudum Family Trust between 06/16/2025 and 07/21/2025 with detailed gross proceeds for each transaction.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions on 08/13/2025. The filing shows acquisition of 11,581 shares at an exercise price of $5.01 and a contemporaneous sale of 11,581 shares at a weighted average price of $48.0459, with sales executed in the range $47.84–$48.32. The report also records a transfer of 62,722 Class A shares from the Oluyemi Okupe Separate Property Trust dated 9-1-2021 to the reporting person’s direct holdings. Post-transaction direct beneficial ownership is reported as 65,665 Class A shares. The exercised options referenced vest per a schedule beginning January 24, 2023, with full monthly vesting thereafter and expire February 23, 2032.
Andrew Dudum, Chief Executive Officer and director of Hims & Hers Health, Inc., reports beneficial ownership equal to 23,820,905 shares of Class A common stock on a fully converted/exercised basis, representing 10.3% of Class A. That total combines shares held directly and in affiliated trusts, Class V common stock that converts into Class A, restricted stock units expected to settle within 60 days, and a large block of stock options exercisable within 60 days.
The filing breaks down the holdings: 9,333,039 Class A shares held by affiliated trusts, 92,313 held directly, 8,377,623 Class V shares, 164,368 Class A shares underlying RSUs expected to settle within 60 days, 5,643,186 options exercisable within 60 days, plus additional options and RSUs subject to vesting; 1,296,568 RSUs not expected to settle within 60 days are excluded from the aggregate amount. The filing also notes that Class V shares convert into Class A upon transfer or by Board resolution after specified trigger conditions.
Capital World Investors (a division of Capital Research and Management Company and affiliated investment management entities) is reported as the beneficial owner of 18,559,302 shares of Hims & Hers Health, Inc., representing 8.6% of the approximately 215.5 million shares outstanding. CWI holds 18,553,317 shares with sole voting power and 18,559,302 shares with sole dispositive power; no shared voting or dispositive power is reported. The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control. The Growth Fund of America is identified in the filing as an account on behalf of which ownership is reported.
Hims & Hers Health insider Melissa Baird filed a Form 144 notifying a proposed sale of 33,333 Class A common shares through Goldman Sachs & Co. LLC, with an aggregate market value of $1,598,650.68. The filing states the shares were acquired on 05/13/2020 as compensation via stock options and that the planned payment method is a cashless exercise/same-day sale. The document lists 217,641,958 shares outstanding for the class and discloses multiple individual sales by Ms. Baird during May–July 2025 with specific dates, share amounts and gross proceeds. No earnings, guidance or other corporate actions are included in this filing.
Hims & Hers Health insider Boughton Soleil, the company's Chief Legal Officer, reported a sale of 2,572 shares of Class A common stock on 08/11/2025 at a reported price of $51.64 per share, leaving 153,021 shares beneficially owned. The filing is a Section 16 Form 4 disclosing this change in beneficial ownership.
Andrew Dudum, identified as Chief Executive Officer, director and a 10% owner of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock on 08/07/2025. The Form 4 shows a disposition of 660,000 shares reported as a sale (code S) at an average weighted price of $50.582 per share.
The filing itemizes the reporting person’s remaining beneficial holdings held indirectly through multiple trusts. The form shows 2,214,769 shares noted alongside the Dudum Family Heritage Trust, and additional indirect trust holdings listed as 1,194,545, 990,410, 1,286,627, 534,491, 186,723, 190,126, 321,657, 1,584,506 and 829,185 shares. The Form 4 was signed by an attorney-in-fact.
Form 144 notice: The filing reports a proposed sale of 2,572 Class A shares of Hims & Hers Health, Inc. through Fidelity Brokerage Services LLC on 08/11/2025, with an aggregate market value of $132,818.08. The company has 217,641,958 shares outstanding. The 2,572 shares were acquired on 06/15/2025 through restricted stock vesting from the issuer and were recorded as compensation.
The filing also lists recent sales by Soleil Boughton over the prior three months: seven transactions between 05/12/2025 and 07/28/2025 totaling 22,207 shares for aggregate gross proceeds of $1,228,936.95. The form includes the standard insider representation regarding material nonpublic information.